BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Status:
Active, not recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of
Brentuximab Vedotin (BV) in combination with EPEM and to assess the toxicity of the
combination of BV with EPEM. In the phase II efficacy will be evaluated.Besides,
progression-free survival (PFS), event-free survival (EFS), overall survival (OS), the
duration of response, the overall response rate (ORR) based on best response will be
evaluated
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea